Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079130 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Different Doses of Indacaterol
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
NCT01079130 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 511 participants.
The verdict
NCT01079130, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
Study Summary
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
Interventions
- DRUG Salmeterol
- DRUG Indacaterol
- DRUG Placebo to Indacaterol
- DRUG Placebo to Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01079130
The ClinicalTrials.gov registry entry for NCT01079130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Salmeterol is the first listed.
NCT01079130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01079130 about?
NCT01079130 is a clinical study titled "Efficacy and Safety of Different Doses of Indacaterol". This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
What is the current status of trial NCT01079130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2010-02.
What interventions are being tested in trial NCT01079130?
The interventions under investigation include: Salmeterol (DRUG), Indacaterol (DRUG), Placebo to Indacaterol (DRUG), Placebo to Salmeterol (DRUG).
Who is sponsoring clinical trial NCT01079130?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.